[Antiphospholipid antibodies: specificity and mechanism of action].
Circulating lupus-type anticoagulant is associated with an increased risk of arterial or venous thrombosis. The laboratory identification of lupus coagulant requires at least 2 different in vitro phospholipid-dependent coagulation techniques: immunological assessment based upon Elisa-type tests using pure phospholipids complements the coagulation procedure, but does not replace it. Circulating lupus anticoagulant is correlated with anti-phospholipid antibodies specific to phosphatidyl serine. Relationships between circulating lupus anticoagulant and anti-cardiolipin seem complex and are discussed. In fact, an entire family of anti-phospholipid antibodies exists, whose relationship with clinical manifestations remains to be determined. The effects of anti-phospholipid antibodies on human endothelial cells are described.
Tobelem
G
G
Institut des Vaisseux et du Sang, Hôpital Lariboisière, Paris.
D000918:Antibody Specificity / Q000276:immunology; D001323:Autoantibodies / Q000032:analysis / Q000276:immunology / Q000502:physiology*; D004730:Endothelium, Vascular / Q000502:physiology; D011464:Epoprostenol / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D010743:Phospholipids / Q000276:immunology*; D013927:Thrombosis / Q000276:immunology
D001323:Autoantibodies; D010743:Phospholipids; D011464:Epoprostenol
Les anticorps antiphospholipides: spécificité et mécanisme d'action.